Theranostics company to test heparin monitor:
This article was originally published in Clinica
PharmaNetics, a Raleigh, North Carolina-based developer of theranostics, has begun clinical testing of a rapid test to monitor the anticoagulant effects of low molecular weight heparin. The Phase I study is to establish the performance of the test card in patients receiving the treatment for arterial or venous thrombosis when optimised, the test will be included in additional clinical trials designed to collect data for a 510(k) US marketing clearance submission later this year, said the company.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.